Tradewinds Capital Management LLC Has $429,000 Stock Holdings in Novo Nordisk A/S (NYSE:NVO)

Tradewinds Capital Management LLC increased its stake in Novo Nordisk A/S (NYSE:NVO) by 2.6% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 4,984 shares of the company’s stock after acquiring an additional 124 shares during the quarter. Tradewinds Capital Management LLC’s holdings in Novo Nordisk A/S were worth $429,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in the stock. Cohen Capital Management Inc. bought a new stake in shares of Novo Nordisk A/S during the 4th quarter valued at about $227,000. Indie Asset Partners LLC increased its holdings in Novo Nordisk A/S by 4.2% in the fourth quarter. Indie Asset Partners LLC now owns 3,128 shares of the company’s stock worth $269,000 after purchasing an additional 126 shares in the last quarter. Dividend Assets Capital LLC lifted its stake in Novo Nordisk A/S by 3.1% in the fourth quarter. Dividend Assets Capital LLC now owns 214,615 shares of the company’s stock valued at $18,461,000 after buying an additional 6,395 shares during the period. Outfitter Financial LLC boosted its holdings in shares of Novo Nordisk A/S by 9.9% during the 4th quarter. Outfitter Financial LLC now owns 8,795 shares of the company’s stock worth $757,000 after buying an additional 795 shares in the last quarter. Finally, Bank of Stockton grew its position in shares of Novo Nordisk A/S by 6.5% during the 4th quarter. Bank of Stockton now owns 8,151 shares of the company’s stock worth $701,000 after buying an additional 499 shares during the period. 11.54% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on NVO shares. BMO Capital Markets dropped their price objective on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating on the stock in a report on Monday, December 23rd. Sanford C. Bernstein raised Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research note on Monday, January 6th. StockNews.com cut Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research note on Sunday, December 29th. BNP Paribas raised Novo Nordisk A/S to a “strong-buy” rating in a research report on Monday, December 2nd. Finally, Morgan Stanley initiated coverage on shares of Novo Nordisk A/S in a research report on Wednesday, February 12th. They issued an “equal weight” rating for the company. Two research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $145.25.

Novo Nordisk A/S Trading Up 5.2 %

Shares of Novo Nordisk A/S stock opened at $88.07 on Friday. The company has a market capitalization of $395.19 billion, a P/E ratio of 26.77, a price-to-earnings-growth ratio of 0.90 and a beta of 0.45. The stock has a fifty day simple moving average of $86.01 and a 200 day simple moving average of $108.07. Novo Nordisk A/S has a 12-month low of $77.82 and a 12-month high of $148.15. The company has a current ratio of 0.74, a quick ratio of 0.55 and a debt-to-equity ratio of 0.62.

Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings results on Wednesday, February 5th. The company reported $0.91 earnings per share for the quarter, beating analysts’ consensus estimates of $0.88 by $0.03. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. On average, sell-side analysts anticipate that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Novo Nordisk A/S Increases Dividend

The firm also recently declared a semi-annual dividend, which will be paid on Tuesday, April 8th. Investors of record on Monday, March 31st will be given a dividend of $0.7874 per share. This represents a dividend yield of 1.2%. This is an increase from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. The ex-dividend date of this dividend is Monday, March 31st. Novo Nordisk A/S’s dividend payout ratio (DPR) is presently 21.88%.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.